# Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

> **NCT02585778** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 517 (actual)

## Conditions studied

- Hypercholesterolaemia

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Placebo
- **DRUG:** Lipid-Modifying Therapy (LMT)
- **DRUG:** Antihyperglycemic Drug

## Key facts

- **NCT ID:** NCT02585778
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-23
- **Primary completion:** 2017-04-03
- **Final completion:** 2017-04-03
- **Target enrollment:** 517 (ACTUAL)
- **Last updated:** 2018-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585778, "Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02585778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*